MRNS

Marinus Pharmaceuticals, Inc.

9.61 USD
-0.14 (-1.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Marinus Pharmaceuticals, Inc. stock is down -2.54% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 February’s closed higher than January. In the last 2 Unusual Options Trades, there were 2 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
26 Dec 14:36 19 Jul, 2024 15.00 CALL 165 86
26 Dec 16:09 19 Jul, 2024 15.00 CALL 298 86

About Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.